← Eichor
Study identifier: NCT05825417 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pulmonary Hypertension: Intensification and Personalisation of Combination Rx

Condition: Pulmonary Arterial Hypertension  ·  Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust

PhasePhase 4
Planned participants40
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The goal of this clinical trial is to evaluate the capacity of implantable/remote technology for early evaluation of drug therapies in patients with pulmonary arterial hypertension (PAH). The main question it aims to answer is whether structured changes in clinical therapy will be detectable using implanted regulatory approved devices. Participants will will be implanted with approved medical devices and will enter into a study of approved drugs to assess physiology, activity and patient reported quality-of-life (QoL) outcomes. Researchers will compare two therapeutic strategies in each individual patient to see if the study design provides enough evidence to personalise drug treatment plans

This description comes directly from the study's public registry record.

Talk to the study team

Shravya Rao  ·  +44 (0) 114 2159550  ·  s.rao@sheffield.ac.uk

Always discuss trial participation with your own doctor first.

Locations (1)

Sheffield Teaching Hospitals NHS FTSheffield, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05825417